Is BMRN a good stock to buy right now?

Based on our 6-factor quantitative model, BIOMARIN PHARMACEUTICAL INC (BMRN) receives a "Reduce" rating with a composite score of 43.9/100. It is ranked #2,023 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 55/100, Momentum 35/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for BMRN?

BIOMARIN PHARMACEUTICAL INC (BMRN) has a "Reduce" rating and 2-star score. The composite score of 43.9 ranks it #2,023 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is BMRN in?

BIOMARIN PHARMACEUTICAL INC operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $11.01 billion. It is classified as a large-cap stock.

Does BMRN pay a dividend?

BMRN does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is BMRN's P/E ratio?

BMRN has a trailing P/E ratio of 21.56x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is BMRN?

BMRN's quality factor score is 50/100. Gross margin: 79.5%. ROE: 8.2% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is BMRN valued compared to peers?

BMRN's value factor score is 55/100 (higher = cheaper). Key multiples: P/E 21.6x, EV/EBITDA 19.0x. Valuation is roughly in line with peers.

What is BMRN's debt level?

BMRN's debt-to-equity ratio is 25%. Sector average: 32%. Low leverage suggests conservative financial management.

BMRN has a beta of 0.81, meaning it tracks the market. Stability score: 70/100.

Does BMRN have high short interest?

BMRN's short interest factor score is 18/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

BMRN Stock Analysis: Reduce (Score 43.9/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
BMRN	-3.14%	-1.75%	-10.45%	-8.24%	-3.18%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-3.08%	-5.35%	-10.78%	-7.88%	-32.70%	-	-	-
Alpha vs Sector	-1.79%	-2.09%	-6.63%	-3.41%	-12.39%	-	-	-

Metric	BMRN	Benchmark
P/E Ratio	21.6x	-9%
EV/EBITDA	19.0x	+200%
Price / Book	1.8x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
BMRN BIOMARIN PHARMACEUTICAL INC	44	50	55	35	21.6x	8.2%	79.5%	16.1%	9.0%	25.0x	$11.0B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.8%	0.8%	0.8%	0.8%	0.8%	0.7%	0.7%	0.8%	0.8%	0.8%	0.8%
Operating Margin %	0.2%	0.1%	0.2%	0.1%	0.1%	-0.0%	-0.0%	-0.1%	-0.1%	-0.0%	-0.7%
EBITDA Margin %	0.2%	0.1%	0.2%	0.1%	0.1%	-0.0%	0.0%	0.0%	0.0%	0.1%	-0.6%
Net Margin %	0.2%	0.1%	0.1%	0.1%	0.1%	-0.0%	0.5%	-0.0%	-0.1%	-0.1%	-0.6%
FCF Margin %	-5.8%	-	-	-	-	-	-1.6%	-5.7%	-8.3%	-15.8%	-33.7%
ROE %	0.1%	0.1%	0.1%	0.0%	0.0%	-0.0%	0.2%	-0.0%	-0.0%	-0.0%	-0.2%
ROA %	0.1%	0.0%	0.1%	0.0%	0.0%	-0.0%	0.1%	-0.0%	-0.0%	-0.0%	-0.2%
ROIC %	8.3%	5.3%	6.8%	2.5%	2.6%	-1.5%	-0.8%	-2.2%	-2.9%	-0.3%	-20.6%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.8%

0.7%

0.8%

Operating Margin %

0.2%

0.1%

0.2%

0.1%

-0.0%

-0.1%

-0.0%

-0.7%

EBITDA Margin %

0.2%

0.1%

0.2%

0.1%

-0.0%

0.0%

0.1%

-0.6%

Net Margin %

0.2%

0.1%

-0.0%

0.5%

-0.0%

-0.1%

-0.6%

FCF Margin %

-5.8%

-1.6%

-5.7%

-8.3%

-15.8%

-33.7%

ROE %

0.1%

0.0%

-0.0%

0.2%

-0.0%

-0.2%

ROA %

0.1%

0.0%

0.1%

0.0%

-0.0%

0.1%

-0.0%

-0.2%

ROIC %

8.3%

5.3%

6.8%

2.5%

2.6%

-1.5%

-0.8%

-2.2%

-2.9%

-0.3%

-20.6%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$3.1B	$3.2B	$2.9B	$2.4B	$2.1B	$1.8B	$1.9B	$1.7B	$1.5B	$1.3B	$1.1B	$890M
	—	$717M	$580M	$515M	$484M	$471M	—	—	—	—	—	—
	$2.5B	$2.5B	$2.3B	$1.9B	$1.6B	$1.4B	$1.3B	$1.3B	$1.2B	$1.1B	$907M	$738M
Gross Margin	79.5%	77.7%	79.7%	78.7%	76.9%	74.5%	71.8%	78.9%	78.9%	81.6%	81.2%	82.9%
	—	$1.2B	$1.0B	$937M	$854M	$759M	—	—	—	—	—	—
Research & Development	—	$922M	$747M	$747M	$650M	$629M	$628M	$715M	$696M	$611M	$662M	$635M
Depreciation	—	—	—	—	—	—	$122M	$117M	$127M	$123M	$128M	$49M
Total Operating Expenses	—	$2.1B	$1.8B	$1.7B	$1.5B	$1.5B	—	—	—	—	—	—
	$568M	$409M	$484M	$158M	$150M	-$82M	-$43M	-$100M	-$124M	-$15M	-$803M	-$111M
EBIT	$568M	$409M	$484M	$158M	$150M	-$82M	-$43M	-$100M	-$124M	-$15M	-$803M	-$111M
EBITDA	$568M	$409M	$484M	$158M	$150M	-$82M	$86M	$23M	$6M	$117M	-$670M	-$42M
Operating Margin	18.2%	12.7%	17.0%	6.5%	7.1%	-4.5%	-2.3%	-5.9%	-8.3%	-1.1%	-71.9%	-12.4%
EBITDA Margin	18.4%	12.7%	17.0%	6.5%	7.1%	-4.5%	4.6%	1.4%	0.4%	8.9%	-60.0%	-4.8%
	—	—	—	$17M	$16M	$15M	$29M	$23M	$44M	$43M	$39M	$38M
	—	$482M	$542M	$189M	$150M	-$75M	—	—	—	—	—	—
Income Tax Expense	—	$134M	$115M	$21M	$8M	-$11M	-$903M	-$71M	-$65M	$81M	-$201M	$17M
	$502M	$349M	$427M	$168M	$142M	-$64M	$854M	-$24M	-$77M	-$117M	-$630M	-$172M
Net Margin	16.1%	10.8%	15.0%	6.9%	6.8%	-3.5%	45.9%	-1.4%	-5.2%	-8.9%	-56.4%	-19.3%
	$1.82	$1.82	$2.25	$0.89	$0.76	$-0.35	$4.72	$-0.13	$-0.44	$-0.67	$-3.80	$-1.07
Diluted EPS	$1.82	$1.80	$2.21	$0.87	$0.75	$-0.35	$4.72	$-0.13	$-0.44	$-0.67	$-3.80	$-1.07
Weighted Avg Basic	—	192M	190M	188M	185M	183M	—	—	—	—	—	—
Weighted Avg Diluted	—	197M	197M	192M	189M	183M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$3.1B

$3.2B

$2.9B

$2.4B

$2.1B

$1.8B

$1.9B

$1.7B

$1.5B

$1.3B

$1.1B

$890M

—

$717M

$580M

$515M

$484M

$471M

—

$2.5B

$2.3B

$1.9B

$1.6B

$1.4B

$1.3B

$1.2B

$1.1B

$907M

$738M

Gross Margin

79.5%

77.7%

79.7%

78.7%

76.9%

74.5%

71.8%

78.9%

81.6%

81.2%

82.9%

—

$1.2B

$1.0B

$937M

$854M

$759M

—

Research & Development

—

$922M

$747M

$650M

$629M

$628M

$715M

$696M

$611M

$662M

$635M

Depreciation

—

$122M

$117M

$127M

$123M

$128M

$49M

Total Operating Expenses

—

$2.1B

$1.8B

$1.7B

$1.5B

—

$568M

$409M

$484M

$158M

$150M

-$82M

-$43M

-$100M

-$124M

-$15M

-$803M

-$111M

EBIT

$568M

$409M

$484M

$158M

$150M

-$82M

-$43M

-$100M

-$124M

-$15M

-$803M

-$111M

EBITDA

$568M

$409M

$484M

$158M

$150M

-$82M

$86M

$23M

$6M

$117M

-$670M

-$42M

Operating Margin

18.2%

12.7%

17.0%

6.5%

7.1%

-4.5%

-2.3%

-5.9%

-8.3%

-1.1%

-71.9%

-12.4%

EBITDA Margin

18.4%

12.7%

17.0%

6.5%

7.1%

-4.5%

4.6%

1.4%

0.4%

8.9%

-60.0%

-4.8%

—

$17M

$16M

$15M

$29M

$23M

$44M

$43M

$39M

$38M

—

$482M

$542M

$189M

$150M

-$75M

—

Income Tax Expense

—

$134M

$115M

$21M

$8M

-$11M

-$903M

-$71M

-$65M

$81M

-$201M

$17M

$502M

$349M

$427M

$168M

$142M

-$64M

$854M

-$24M

-$77M

-$117M

-$630M

-$172M

Net Margin

16.1%

10.8%

15.0%

6.9%

6.8%

-3.5%

45.9%

-1.4%

-5.2%

-8.9%

-56.4%

-19.3%

$1.82

$2.25

$0.89

$0.76

$-0.35

$4.72

$-0.13

$-0.44

$-0.67

$-3.80

$-1.07

Diluted EPS

$1.82

$1.80

$2.21

$0.87

$0.75

$-0.35

$4.72

$-0.13

$-0.44

$-0.67

$-3.80

$-1.07

Weighted Avg Basic

—

192M

190M

188M

185M

183M

—

Weighted Avg Diluted

—

197M

192M

189M

183M

—

BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does BIOMARIN PHARMACEUTICAL INC Do?

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California. BIOMARIN PHARMACEUTICAL INC (BMRN) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jean-Jacques Bienaimé and employs approximately 3,080 people, headquartered in Novato, California. With a market capitalization of $11.0B, BMRN is one of the prominent companies in the Healthcare sector.

BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Rating — Reduce (April 2026)

As of April 2026, BIOMARIN PHARMACEUTICAL INC receives a Reduce rating with a composite score of 43.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BMRN ranks #2,023 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BIOMARIN PHARMACEUTICAL INC ranks #219 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BMRN Stock Price and 52-Week Range

BIOMARIN PHARMACEUTICAL INC (BMRN) currently trades at $54.55. The stock lost $1.75 (3.1%) in the most recent trading session. The 52-week high for BMRN is $73.18, which means the stock is currently trading -25.5% from its annual peak. The 52-week low is $50.76, putting the stock 7.5% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.

Is BMRN Overvalued or Undervalued? — Valuation Analysis

BIOMARIN PHARMACEUTICAL INC (BMRN) carries a value factor score of 55/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 21.56x, compared to the Healthcare sector average of 23.63x — a discount of 9%. The price-to-book ratio stands at 1.78x, versus the sector average of 2.75x. The price-to-sales ratio is 3.50x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BMRN trades at 19.04x EV/EBITDA, versus 6.34x for the sector.

Overall, BMRN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

BIOMARIN PHARMACEUTICAL INC Profitability — ROE, Margins, and Quality Score

BIOMARIN PHARMACEUTICAL INC (BMRN) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 8.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 6.6% versus the sector average of -33.1%.

On a margin basis, BIOMARIN PHARMACEUTICAL INC reports gross margins of 79.5%, compared to 71.5% for the sector. The operating margin is 18.2% (sector: -66.1%). Net profit margin stands at 16.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 9.0% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

BMRN Debt, Balance Sheet, and Financial Health

BIOMARIN PHARMACEUTICAL INC has a debt-to-equity ratio of 25.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.21x, indicating strong short-term liquidity. Total debt on the balance sheet is $597M. Cash and equivalents stand at $1.25B.

BMRN has a beta of 0.81, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for BIOMARIN PHARMACEUTICAL INC is 70/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

BIOMARIN PHARMACEUTICAL INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, BIOMARIN PHARMACEUTICAL INC reported revenue of $3.09B and earnings per share (EPS) of $1.82. Net income for the quarter was $502M. Gross margin was 79.5%. Operating income came in at $568M.

In FY 2025, BIOMARIN PHARMACEUTICAL INC reported revenue of $3.22B and earnings per share (EPS) of $1.82. Net income for the quarter was $349M. Gross margin was 77.7%. Revenue grew 12.9% year-over-year compared to FY 2024. Operating income came in at $409M.

In Q3 2025, BIOMARIN PHARMACEUTICAL INC reported revenue of $776M and earnings per share (EPS) of $-0.16. Net income for the quarter was $-31M. Gross margin was 82.0%. Revenue grew 4.1% year-over-year compared to Q3 2024. Operating income came in at $-47M.

In Q2 2025, BIOMARIN PHARMACEUTICAL INC reported revenue of $825M and earnings per share (EPS) of $1.25. Net income for the quarter was $241M. Gross margin was 81.8%. Revenue grew 15.9% year-over-year compared to Q2 2024. Operating income came in at $277M.

Over the past 8 quarters, BIOMARIN PHARMACEUTICAL INC has demonstrated a growth trajectory, with revenue expanding from $712M to $3.09B. Investors analyzing BMRN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BMRN Dividend Yield and Income Analysis

BIOMARIN PHARMACEUTICAL INC (BMRN) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BMRN Momentum and Technical Analysis Profile

BIOMARIN PHARMACEUTICAL INC (BMRN) has a momentum factor score of 35/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

BMRN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BIOMARIN PHARMACEUTICAL INC (BMRN) ranks #219 out of 838 stocks based on the Blank Capital composite score. This places BMRN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BMRN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BMRN vs S&P 500 (SPY) comparison to assess how BIOMARIN PHARMACEUTICAL INC stacks up against the broader market across all factor dimensions.

BMRN Next Earnings Date

No upcoming earnings date has been announced for BIOMARIN PHARMACEUTICAL INC (BMRN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BMRN? — Investment Thesis Summary

The quantitative profile for BIOMARIN PHARMACEUTICAL INC suggests caution. Momentum is weak at 35/100, a headwind for near-term performance. Low volatility (stability score 70/100) reduces downside risk.

In summary, BIOMARIN PHARMACEUTICAL INC (BMRN) earns a Reduce rating with a composite score of 43.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BMRN stock.

Related Resources for BMRN Investors

Explore more research and tools: BMRN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BMRN head-to-head with peers: BMRN vs AZN, BMRN vs SLGL, BMRN vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Here is Why BioMarin (BMRN) is Projected to Rally

How Investors May Respond To Ascendis Pharma (ASND) Growth‑Disorder Data And New Board Appointment

If You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After A 42.7% Three-Year Share Price Fall

2 Profitable Stocks with Promising Prospects and 1 Facing Challenges

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does BIOMARIN PHARMACEUTICAL INC Do?

BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Rating — Reduce (April 2026)

BMRN Stock Price and 52-Week Range

Is BMRN Overvalued or Undervalued? — Valuation Analysis

BIOMARIN PHARMACEUTICAL INC Profitability — ROE, Margins, and Quality Score

BMRN Debt, Balance Sheet, and Financial Health

BIOMARIN PHARMACEUTICAL INC Revenue and Earnings History — Quarterly Trend

BMRN Dividend Yield and Income Analysis

BMRN Momentum and Technical Analysis Profile

BMRN vs Competitors — Healthcare Sector Ranking and Peer Comparison

BMRN Next Earnings Date

Should You Buy BMRN? — Investment Thesis Summary

Related Resources for BMRN Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Here is Why BioMarin (BMRN) is Projected to Rally

How Investors May Respond To Ascendis Pharma (ASND) Growth‑Disorder Data And New Board Appointment

If You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After A 42.7% Three-Year Share Price Fall

2 Profitable Stocks with Promising Prospects and 1 Facing Challenges